Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies

Molecular Immunology

Volumn 67, Issue 2, 2015, Pages 107-116

  Shor, Boris ^a   Gerber, Hans Peter ^a   Sapra, Puja ^a  

^a PFIZER INC   (United States)

Author keywords

Antibody drug conjugate; Cytotoxic compounds; DNA damaging agents; Hematologic malignancies; Non Hodgkin's lymphoma; Pharmacology

Indexed keywords

CALICHEAMICIN; CD22 ANTIGEN; INOTUZUMAB OZOGAMICIN; RITUXIMAB; ANTIBODY CONJUGATE; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER STAGING; CELL CYCLE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; LARGE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RELAPSE; REVIEW; TUMOR REGRESSION; CELL PROLIFERATION; DOUBLE STRANDED DNA BREAK; DRUG EFFECTS; DRUG SCREENING; GENETICS; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN; PROCEDURES;

ANTIBODIES, MONOCLONAL, HUMANIZED; CELL PROLIFERATION; DNA BREAKS, DOUBLE-STRANDED; DRUG SCREENING ASSAYS, ANTITUMOR; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN; SIALIC ACID BINDING IG-LIKE LECTIN 2;

EID: 84939267428     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2014.09.014     Document Type: Review

References (61)

1. Advani A., Coiffier B., Czuczman M.S., Dreyling M., Foran J., Gine E., Gisselbrecht C., Ketterer N., Nasta S., Rohatiner A., et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J. Clin. Oncol. 2010, 28:2085-2093.
2. Aneja S., Yu J.B. Comparative effectiveness research in radiation oncology: stereotactic radiosurgery, hypofractionation, and brachytherapy. Semin. Radiat. Oncol. 2014, 24:35-42.
3. Beeram M., Krop I.E., Burris H.A., Girish S.R., Yu W., Lu M.W., Holden S.N., Modi S. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer 2012, 118:5733-5740.
4. Bellomo G., Vairetti M., Stivala L., Mirabelli F., Richelmi P., Orrenius S. Demonstration of nuclear compartmentalization of glutathione in hepatocytes. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:4412-4416.
5. Bernstein I.D. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 2000, 14:474-475.
6. Burnett A.K., Hills R.K., Milligan D., Kjeldsen L., Kell J., Russell N.H., Yin J.A., Hunter A., Goldstone A.H., Wheatley K. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J. Clin. Oncol. 2011, 29:369-377.
7. Castaigne S., Pautas C., Terre C., Raffoux E., Bordessoule D., Bastie J.N., Legrand O., Thomas X., Turlure P., Reman O., et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012, 379:1508-1516.
8. Chabner B.A., Loeffler J. Cancer chemotherapy and radiation therapy. Oxford Textbook of Medicine 2010, Oxford University Press, Oxford, UK. 5th ed. T.M.C. David, A. Warrell, D. John (Eds.).
9. Damle N.K. Tumour-targeted chemotherapy with immunoconjugates of calicheamicin. Expert Opin. Biol. Ther. 2004, 4:1445-1452.
10. Daridon C., Blassfeld D., Reiter K., Mei H.E., Giesecke C., Goldenberg D.M., Hansen A., Hostmann A., Frolich D., Dorner T. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res. Ther. 2010, 12:R204.
11. de Vries J.F., Zwaan C.M., De Bie M., Voerman J.S., den Boer M.L., van Dongen J.J., van der Velden V.H. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 2012, 26:255-264.
12. Dedon P.C., Goldberg I.H. Free-radical mechanisms involved in the formation of sequence-dependent bistranded DNA lesions by the antitumor antibiotics bleomycin, neocarzinostatin, and calicheamicin. Chem. Res. Toxicol. 1992, 5:311-332.
13. DiJoseph J.F., Armellino D.C., Boghaert E.R., Khandke K., Dougher M.M., Sridharan L., Kunz A., Hamann P.R., Gorovits B., Udata C., et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004, 103:1807-1814.
14. Dijoseph J.F., Dougher M.M., Armellino D.C., Evans D.Y., Damle N.K. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 2007, 21:2240-2245.
15. DiJoseph J.F., Dougher M.M., Evans D.Y., Zhou B.B., Damle N.K. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. Cancer Chemother. Pharmacol. 2011, 67:741-749.
16. DiJoseph J.F., Dougher M.M., Kalyandrug L.B., Armellino D.C., Boghaert E.R., Hamann P.R., Moran J.K., Damle N.K. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin. Cancer Res. 2006, 12:242-249.
17. DiJoseph J.F., Goad M.E., Dougher M.M., Boghaert E.R., Kunz A., Hamann P.R., Damle N.K. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin. Cancer Res. 2004, 10:8620-8629.
18. DiJoseph J.F., Popplewell A., Tickle S., Ladyman H., Lawson A., Kunz A., Khandke K., Armellino D.C., Boghaert E.R., Hamann P., et al. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22. Cancer Immunol. Immunother. 2005, 54:11-24.
19. Doody G.M., Justement L.B., Delibrias C.C., Matthews R.J., Lin J., Thomas M.L., Fearon D.T. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science 1995, 269:242-244.
20. Dorken B., Moldenhauer G., Pezzutto A., Schwartz R., Feller A., Kiesel S., Nadler L.M. HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J. Immunol. 1986, 136:4470-4479.
21. Drak J., Iwasawa N., Danishefsky S., Crothers D.M. The carbohydrate domain of calicheamicin gamma I1 determines its sequence specificity for DNA cleavage. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:7464-7468.
22. Ellestad G.A. Structural and conformational features relevant to the anti-tumor activity of calicheamicin gamma 1I. Chirality 2011, 23:660-671.
23. Fanale M.A., Forero-Torres A., Rosenblatt J.D., Advani R.H., Franklin A.R., Kennedy D.A., Han T.H., Sievers E.L., Bartlett N.L. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin. Cancer Res. 2012, 18:248-255.
24. Fayad L., Offner F., Smith M.R., Verhoef G., Johnson P., Kaufman J.L., Rohatiner A., Advani A., Foran J., Hess G., et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J. Clin. Oncol. 2013, 31:573-583.
25. Gerber H.P., Koehn F.E., Abraham R.T. The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat. Prod. Rep. 2013, 30:625-639.
26. Goy A., Leach J., Tsai M., Foran J.J.F., Wagner-Johnston N., Ehmann C., Egyed M., Ando K., Hatake K., et al. Inotuzumab ozogamicin in patients with indolent b-cell non-Hodgkin lymphoma refractory to Rituximab and chemotherapy or radioimmunotherapy. Haematologica 2012, 97:324-325.
27. Greenstein M., Wildey M.J., WM M. The biochemical induction assay and its application in the detection of the calicheamicins. Enediyne Antibiotics as Antitumor Agents 1993, 17-27. Marcel Dekker, Inc., New York, NY. T.W.D. Donald, B. Borders (Eds.).
28. Hamann P.R., Hinman L.M., Beyer C.F., Lindh D., Upeslacis J., Flowers D.A., Bernstein I. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug. Chem. 2002, 13:40-46.
29. Hamann P.R., Hinman L.M., Hollander I., Beyer C.F., Lindh D., Holcomb R., Hallett W., Tsou H.R., Upeslacis J., Shochat D., et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 2002, 13:47-58.
30. Haso W., Lee D.W., Shah N.N., Stetler-Stevenson M., Yuan C.M., Pastan I.H., Dimitrov D.S., Morgan R.A., FitzGerald D.J., Barrett D.M., et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 2013, 121:1165-1174.
31. Ho S.N., Boyer S.H., Schreiber S.L., Danishefsky S.J., Crabtree G.R. Specific inhibition of formation of transcription complexes by a calicheamicin oligosaccharide: a paradigm for the development of transcriptional antagonists. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:9203-9207.
32. N. Howlader, A. Noone, M. Krapcho, J. Garshell, N. Neyman, S.F. Altekruse, C.L. Kosary, M. Yu, J. Ruhl, Z. Tatalovich, H. Cho, A. Mariotto, D.R. Lewis, H.S. Chen, E.J. Feuer, K.A. Cronin (Eds.). SEER Cancer Statistics Review (CSR) 1975-2010 2013, NIH publication, U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, Bethesda, MD.
33. Ikemoto N., Kumar R.A., Ling T.T., Ellestad G.A., Danishefsky S.J., Patel D.J. Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:10506-10510.
34. John B., Herrin B.R., Raman C., Wang Y.N., Bobbitt K.R., Brody B.A., Justement L.B. The B cell coreceptor CD22 associates with AP50, a clathrin-coated pit adapter protein, via tyrosine-dependent interaction. J. Immunol. 2003, 170:3534-3543.
35. Kantarjian H., Thomas D., Jorgensen J., Jabbour E., Kebriaei P., Rytting M., York S., Ravandi F., Kwari M., Faderl S., et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012, 13:403-411.
36. Kantarjian H., Thomas D., Jorgensen J., Kebriaei P., Jabbour E., Rytting M., York S., Ravandi F., Garris R., Kwari M., et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013, 119:2728-2736.
37. Lee M., Durr F., Hinman L., Hamann P., EG A. The Calicheamicins 1993, 31-65. JAI Press, USA. B.E. Maryanoff, C.A. Maryanoff (Eds.).
38. Lee M.D., Dunne T.S., Chang C.C., Siegel M.M., Morton G.O., Ellestad G.A., McGahren W.J., Borders D.B. Calicheamicins, a novel family of antitumor antibiotics. 4. Structure elucidation of calicheamicins .beta.1Br, .gamma.1Br, .alpha.2I, .alpha.3I, .beta.1I.gamma.1I, and .delta.1I. J. Am. Chem. Soc. 1992, 114:985-997.
39. Lee M.D., Manning J.K., Williams D.R., Kuck N.A., Testa R.T., Borders D.B. Calicheamicins, a novel family of antitumor antibiotics, 3. Isolation, purification and characterization of calicheamicins beta 1Br, gamma 1Br, alpha 2I, alpha 3I, beta 1I, gamma 1I and delta 1I. J. Antibiot. 1989, 42:1070-1087.
40. Mager D.E., Jusko W.J. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J. Pharmacokinet. Pharmacodyn. 2001, 28:507-532.
41. Marinelli M., Raponi S., Del Giudice I., De Propris M.S., Nanni M., Intoppa S., Milani M.L., Mauro F.R., Guarini A., Foa R. Is the aberrant expression of p53 by immunocytochemistry a surrogate marker of TP53 mutation and/or deletion in chronic lymphocytic leukemia?. Am. J. Clin. Pathol. 2011, 135:173-174.
42. Meijer R.T., Koopmans R.P., ten Berge I.J., Schellekens P.T. Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen. J. Pharmacol. Exp. Ther. 2002, 300:346-353.
43. Nicolaou K.C., Smith A.L., Yue E.W. Chemistry and biology of natural and designed enediynes. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:5881-5888.
44. Nitschke L. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol. Rev. 2009, 230:128-143.
45. O'Brien S., Thomas D.A., Jorgensen J.L., Kebriaei P., Ravandi F., Kwari M., Faderl S., Cortes J.E., Jabbour E.J., York S., et al. Experience with 2 dose schedules of inotuzumab ozogamicin, single dose, and weekly, in refractory-relapsed acute lymphocytic leukemia (ALL). ASH Annual Meeting Abstract, vol. 120 2012, 671-680.
46. Ogura M., Hatake K., Ando K., Tobinai K., Tokushige K., Ono C., Ishibashi T., Vandendries E. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 2012, 103:933-938.
47. Ogura M., Tobinai K., Hatake K., Uchida T., Kasai M., Oyama T., Suzuki T., Kobayashi Y., Watanabe T., Azuma T., et al. Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Sci. 2010, 101:1840-1845.
48. Ogura M., Uchida T., MacDonald D.A., Hatake K., Davies A., Sangha R., Crump M., Thieblemont C., Ishibashi T., Hua S., et al. An open-label, phase i study of r-cvp in combination with inotuzumab ozogamicin in patients with relapsed/refractory CD22-positive B-cell non-Hodgkin lymphoma. ASH Annual Meeting Abstract, vol. 118 2011, 3715-3720.
49. Olejniczak S.H., Stewart C.C., Donohue K., Czuczman M.S. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol. Investig. 2006, 35:93-114.
50. Petersdorf S., Kopecky K., Stuart R.K., Larson R.A., Nevill T.J., Stenke L., Slovak M.L., Tallman M.S., Willman C.L., Erba H., et al. Preliminary results of southwest oncology group study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. ASH Annual Meeting Abstract, vol. 114 2009, 790-800.
51. Pfizer Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility 2013, Retrieved from: http://www.pfizer.com/news/press-release/press-release-archive-detail/pfizer_discontinues_phase_3_study_of_inotuzumab_ozogamicin_in_relapsed_or_refractory_aggressive_non_hodgkin_lymphoma_nhl_due_to_futility (press release. May 20, 2013).
52. Piccaluga P.P., Arpinati M., Candoni A., Laterza C., Paolini S., Gazzola A., Sabattini E., Visani G., Pileri S.A. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk. Lymphoma 2011, 52:325-327.
53. Raponi S., De Propris M.S., Intoppa S., Milani M.L., Vitale A., Elia L., Perbellini O., Pizzolo G., Foa R., Guarini A. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk. Lymphoma 2011, 52:1098-1107.
54. Rytting M., Triche L., Thomas D., O'Brien S., Kantarjian H. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr. Blood Cancer 2014, 61:369-372.
55. Sapra P., Betts A., Boni J. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates. Exp. Rev. Clin. Pharmacol. 2013, 6:541-555.
56. Sapra P., Dijoseph J., Gerber H.-P. Calicheamicin antibody-drug conjugates and beyond. Drug Delivery in Oncology 2011, 395-410. Wiley-VCH Verlag GmbH & Co KGaA, Weinheim, Germany.
57. Siegel R., Naishadham D., Jemal A. Cancer statistics. Cancer J. Clin. 2013, 63:11-30.
58. Thorson J.S., Sievers E.L., Ahlert J., Shepard E., Whitwam R.E., Onwueme K.C., Ruppen M. Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research. Curr. Pharm. Des. 2000, 6:1841-1879.
59. Wagner-Johnston N., Goy A., Feldman T., Goh Y.T., Suh C., Sweetenham J.W., Powell C., Sullivan S.T., Vandendries E.R., Gisselbrecht C. Anti-CD22 Immunoconjugate inotuzumab ozogamicin (CMC-544)+ Rituximab in relapsed DLBCL patients followed by stem cell transplantation: preliminary safety and efficacy. ASH Annual Meeting Abstract, vol. 116 2010, 2883-2890.
60. Zein N., Poncin M., Nilakantan R., Ellestad G.A. Calicheamicin gamma 1I and DNA: molecular recognition process responsible for site-specificity. Science 1989, 244:697-699.
61. Zein N., Sinha A.M., McGahren W.J., Ellestad G.A. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988, 240:1198-1201.